Abbvie Inc (ABBV)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ABBV? Forum Prognose Dividendenhistorie

Warum fällt Abbvie Inc-Aktie (ABBV)?

Wir haben während der Handelssitzung 2024-04-26 einen Rückgang der Aktie Abbvie Inc (ABBV) um 5.36% festgestellt. Obwohl dies auf normale Volatilität oder verschiedene interne und externe Faktoren zurückzuführen sein kann, beachten Sie bitte, dass wir die Situation aktiv beobachten und so schnell wie möglich zeitnahe Updates bereitstellen!

2024-04-04:

Abbvie (ABBV) stock dropped by 5.32% following the company's revision of its full-year and Q1 guidance, reflecting an unfavorable impact on earnings. This marked the biggest intraday decline in more than five months for the North Chicago-based pharma giant.

Revised Guidance: AbbVie revised its full-year and Q1 2024 guidance for adjusted diluted earnings to $10.97–$11.17 and $2.18–$2.22 per share, respectively. This adjustment accounts for acquired in-process R&D and milestones expenses.
Impact on Earnings: The company stated that $164 million in acquired IPR&D and milestones expense for Q1 2024 would have a $0.08 unfavorable impact on GAAP and non-GAAP diluted earnings per share for the quarter.
Previous Guidance Adjustment: In February, AbbVie lowered its Q1 adjusted diluted EPS guidance to $2.26–$2.30, including a $0.42 per share dilutive impact related to its Immunogen acquisition and pending buyout deal with Cerevel Therapeutics (CERE). Despite this, the company reaffirmed its full-year adjusted diluted EPS guidance at $11.05–$11.25 for 2024.
Analysts' View: The correction made to the story clarified AbbVie's full-year earnings outlook, highlighting the importance of accurate financial reporting and its impact on stock performance.